Edition:
United States

Vital Therapies Inc (VTL.OQ)

VTL.OQ on NASDAQ Stock Exchange Global Select Market

5.75USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$5.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,602
52-wk High
$7.20
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Vital Therapies Files For Up To $200 Million Mixed Shelf
Friday, 25 May 2018 04:32pm EDT 

May 25 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES FILES FOR UP TO $200 MILLION MIXED SHELF - SEC FILING.VITAL THERAPIES ALSO FILES FOR SECONDARY OFFERING OF UP TO 2.5 MILLION SHARES OFFERED BY SELLING STOCKHOLDERS.VITAL THERAPIES - SELLING STOCKHOLDERS MAY FROM TIME TO TIME, AFTER CO ANNOUNCES TOPLINE DATA FOR VTL-308 CLINICAL STUDY, OFFER UP TO 2.5 MILLION SHARES.  Full Article

Vital Therapies Q1 Loss Per Share $0.34
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.34.Q1 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON REUTERS I/B/E/S.  Full Article

Vital Therapies Announces Q4 Loss Per Share $0.35
Tuesday, 13 Mar 2018 04:01pm EDT 

March 13 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.35.Q4 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.BELIEVES ITS CURRENT CASH POSITION SHOULD PROVIDE FUNDING THROUGH Q1 OF 2019​.  Full Article

Vital Therapies Appoints Russell J. Cox As Chief Executive Officer And Board Member
Monday, 4 Dec 2017 04:29pm EST 

Dec 4 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES APPOINTS RUSSELL J. COX AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER EFFECTIVE JANUARY 3, 2018.VITAL THERAPIES INC - COX WILL SUCCEED TERRY WINTERS.  Full Article

Vital Therapies reports Q3 loss per share $0.30
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Vital Therapies Inc ::Vital therapies announces third quarter 2017 financial results.Q3 loss per share $0.30.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Vital Therapies-believes current cash position could provide funding through q1 2019, past expected announcement of VTL-308 top-line trial results​.  Full Article

Vital Therapies Q2 loss per share $0.29
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Vital Therapies Inc ::Vital Therapies announces second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Vital Therapies Inc - research and development expenses increased to $9.8 million for three months ended June 30 versus $6.9 million for 3 months ended June 30, 2016​.  Full Article

Vital Therapies announces Q1 loss per share $0.39
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Vital Therapies Inc :Vital Therapies announces first quarter 2017 financial results.Q1 loss per share $0.39.Q1 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Vital Therapies announces exercise in full of underwriters' option to purchase additional shares of common stock in public offering
Wednesday, 29 Mar 2017 04:01pm EDT 

Vital Therapies Inc : Vital Therapies announces exercise in full of underwriters’ option to purchase additional shares of common stock in public offering . Vital Therapies Inc - underwriters have exercised in full their option to purchase an additional 1.3 million shares of its common stock .Vital Therapies Inc - Vital Therapies currently plans to use net proceeds from this offering for continuing clinical development of ELAD system.  Full Article

Vital Therapies announces pricing of public offering of common stock
Wednesday, 22 Mar 2017 09:07am EDT 

Vital Therapies Inc : Vital Therapies announces pricing of public offering of common stock .Says public offering of 8.75 million common shares priced at $4.00 per share.  Full Article

Vital Therapies announces proposed public offering of common stock
Tuesday, 21 Mar 2017 04:01pm EDT 

Vital Therapies Inc : Vital Therapies announces proposed public offering of common stock .Vital Therapies Inc- plans to use net proceeds from offering for continuing clinical development of elad system.  Full Article

BRIEF-Vital Therapies Q1 Loss Per Share $0.34

* VITAL THERAPIES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS